These findings have demonstrated the oncogenic functions of AGAP2-AS1 in NSCLC, gastric cancer, and breast cancer, where the involvement of epigenetic proteins like EZH2, LSD1, and CREB-binding protein (CBP) enables it to effectively suppress the transcription of downstream targets. The gene discussed is AGAP2; the disease is breast carcinoma.